Search


Current filters:

Start a new search
Add filters:

Use filters to refine the search results.


Results 1-10 of 55 (Search time: 0.003 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2012Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculatureKazenwadel, J.; Secker, G.; Liu, Y.; Rosenfeld, J.; Wildin, R.; Cuellar-Rodriguez, J.; Hsu, A.; Dyack, S.; Fernandez, C.; Chong, C.; Babic, M.; Bardy, P.; Shimamura, A.; Zhang, M.; Walsh, T.; Holland, S.; Hickstein, D.; Horwitz, M.; Hahn, C.; Scott, H.; et al.
2015Progesterone receptor modulates ERα action in breast cancerMohammed, H.; Russell, I.; Stark, R.; Rueda, O.; Hickey, T.; Tarulli, G.; Serandour, A.; Birrell, S.; Bruna, A.; Saadi, A.; Menon, S.; Hadfield, J.; Pugh, M.; Raj, G.; Brown, G.; D'Santos, C.; Robinson, J.; Silva, G.; Launchbury, R.; Perou, C.; et al.
2016TBC1D24 genotype-phenotype correlationBalestrini, S.; Milh, M.; Castiglioni, C.; Lüthy, K.; Finelli, M.; Verstreken, P.; Cardon, A.; Stražišar, B.; Holder, J.; Lesca, G.; Mancardi, M.; Poulat, A.; Repetto, G.; Banka, S.; Bilo, L.; Birkeland, L.; Bosch, F.; Brockmann, K.; Cross, J.; Doummar, D.; et al.
2004A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models.Emanuel, S.; Gruninger, R.; Fuentas, P.; Connolly, P.; Seamon, J.; Hazel, S.; Tominovich, R.; Hollister, B.; Napier, C.; D'Andrea, M.; Reuman, M.; Bignan, G.; Tuman, R.; Johnson, D.; Moffatt, D.; Batchelor, M.; Foley, A.; O'Connell, J.; Allen, R.; Perry, M.; et al.
2012The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinomaPerez-Mancera, P.; Rust, A.; van der Weyden, L.; Kristiansen, G.; Li, A.; Sarver, A.; Silverstein, K.; Grützmann, R.; Aust, D.; Rümmele, P.; Knösel, T.; Herd, C.; Stemple, D.; Kettleborough, R.; Brosnan, J.; Li, A.; Morgan, R.; Knight, S.; Yu, J.; Stegeman, S.; et al.
2012PRRT2 mutations cause benign familial infantile epilepsy and infantile convulsions with choreoathetosis syndromeHeron, S.; Grinton, B.; Kivity, S.; Afawi, Z.; Zuberi, S.; Hughes, J.; Pridmore, C.; Hodgson, B.; Iona, X.; Sadleir, L.; Pelekanos, J.; Herlenius, E.; Goldberg-Stern, H.; Bassan, H.; Haan, E.; Korczyn, A.; Gardner, A.; Corbett, M.; Gecz, J.; Thomas, P.; et al.
2019Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancerWatt, M.J.; Clark, A.K.; Selth, L.A.; Haynes, V.R.; Lister, N.; Rebello, R.; Porter, L.H.; Niranjan, B.; Whitby, S.T.; Lo, J.; Huang, C.; Schittenhelm, R.B.; Anderson, K.E.; Furic, L.; Wijayaratne, P.R.; Matzaris, M.; Montgomery, M.K.; Papargiris, M.; Norden, S.; Febbraio, M.; et al.
2016Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemiaGu, Z.; Churchman, M.; Roberts, K.; Li, Y.; Liu, Y.; Harvey, R.; McCastlain, K.; Reshmi, S.; Payne-Turner, D.; Iacobucci, I.; Shao, Y.; Chen, I.; Valentine, M.; Pei, D.; Mungall, K.; Mungall, A.; Ma, Y.; Moore, R.; Marra, M.; Stonerock, E.; et al.
2013Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitorsWaibel, M.; Solomon, V.; Knight, D.; Ralli, R.; Kim, S.; Banks, K.; Vidacs, E.; Virely, C.; Sia, K.; Bracken, L.; Collins-Underwood, R.; Drenberg, C.; Ramsey, L.; Meyer, S.; Takiguchi, M.; Dickins, R.; Levine, R.; Ghysdael, J.; Dawson, M.; Lock, R.; et al.
2016CXCR5⁺ follicular cytotoxic T cells control viral infection in B cell folliclesLeong, Y.; Chen, Y.; Ong, H.; Wu, D.; Man, K.; Deleage, C.; Minnich, M.; Meckiff, B.; Wei, Y.; Hou, Z.; Zotos, D.; Fenix, K.; Atnerkar, A.; Preston, S.; Chipman, J.; Beilman, G.; Allison, C.; Sun, L.; Wang, P.; Xu, J.; et al.